Suven Pharmaceuticals Limited

NSEI:SUVENPHAR 주식 보고서

시가총액: ₹337.0b

Suven Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

Suven Pharmaceuticals 의 총 주주 지분은 ₹20.5B 이고 총 부채는 ₹650.0M, 이는 부채 대 자기자본 비율을 3.2% 로 가져옵니다. 총자산과 총부채는 각각 ₹22.5B 및 ₹2.0B 입니다. Suven Pharmaceuticals 의 EBIT는 ₹2.7B 이며 이자보상배율은 51.4 입니다. ₹8.2B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

3.2%

부채 비율

₹649.96m

부채

이자 보상 비율51.4x
현금₹8.21b
주식₹20.51b
총 부채₹2.03b
총 자산₹22.54b

최근 재무 상태 업데이트

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07
Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03
Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04
Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13
With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08
Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

재무 상태 분석

단기부채: SUVENPHAR 의 단기 자산 ( ₹12.6B )이 단기 부채( ₹1.1B ).

장기 부채: SUVENPHAR 의 단기 자산( ₹12.6B )이 장기 부채( ₹965.3M ).


부채 대 자본 내역 및 분석

부채 수준: SUVENPHAR 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: SUVENPHAR 의 부채 대 자기자본 비율은 지난 5년간 16.6% 에서 3.2% 로 감소했습니다.

부채 범위: SUVENPHAR 의 부채는 영업 현금 흐름 ( 551.5% )에 의해 잘 충당되었습니다.

이자 보장: SUVENPHAR 의 부채에 대한 이자 지급EBIT( 51.4 x 적용 범위)로 잘 충당됩니다.


대차 대조표


건강한 기업 발견하기